Development of plant-produced protein body vaccine candidates for bluetongue virus


Show simple item record van Zyl, Albertha R Meyers, Ann E Rybicki, Edward P 2017-06-05T08:47:24Z 2017-06-05T08:47:24Z 2017-05-30
dc.identifier.citation van Zyl, A. R., Meyers, A. E., & Rybicki, E. P. (2017). Development of plant-produced protein body vaccine candidates for bluetongue virus. BMC Biotechnology, 17(1), 47.
dc.description.abstract Background: Bluetongue is a disease of domestic and wild ruminants caused by bluetongue virus serotypes (BTV), which have caused serious outbreaks worldwide. Commercially available vaccines are live-attenuated or inactivated virus strains: these are effective, but there is the risk of reversion to virulence or reassortment with circulating strains for live virus, and residual live virus for the inactivated vaccines. The live-attenuated virus vaccines are not able to distinguish naturally infected animals from vaccinated animals (DIVA compliant). Recombinant vaccines are preferable to minimize the risks associated with these vaccines, and would also enable the development of candidate vaccines that are DIVA-compliant. Results: In this study, two novel protein body (PB) plant-produced vaccines were developed, Zera®-VP2ep and Zera®-VP2. Zera®-VP2ep contained B-cell epitope sequences of multiple BTV serotypes and Zera®-VP2 contained the full-length BTV-8 VP2 codon-optimised sequence. In addition to fulfilling the DIVA requirement, Zera®-VP2ep was aimed at being multivalent with the ability to stimulate an immune response to several BTV serotypes. Both these candidate vaccines were successfully made in N. benthamiana via transient Agrobacterium-mediated expression, and in situ TEM analysis showed that the expressed proteins accumulated within the cytoplasm of plant cells in dense membrane-defined PBs. The peptide sequences included in Zera®-VP2ep contained epitopes that bound antibodies produced against native VP2. Preliminary murine immunogenicity studies showed that the PB vaccine candidates elicited anti-VP2 immune responses in mice without the use of adjuvant. Conclusions: These proof of concept results demonstrate that Zera®-VP2ep and Zera®-VP2 have potential as BTV vaccines and their development should be further investigated.
dc.language.iso en
dc.publisher BioMed Central
dc.subject.other Bluetongue virus
dc.subject.other Protein body
dc.subject.other Nicotiana benthamiana
dc.subject.other Vaccine
dc.subject.other Zera®
dc.title Development of plant-produced protein body vaccine candidates for bluetongue virus
dc.type Journal Article
dc.type Journal Article en_ZA 2017-06-04T03:38:10Z
dc.rights.holder The Author(s).
uct.type.publication Research en_ZA
uct.type.resource Article en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Science en_ZA
dc.publisher.department Department of Molecular and Cell Biology en_ZA
uct.type.filetype Text
uct.type.filetype Image

Files in this item

This item appears in the following Collection(s)

Show simple item record